Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
19/11/2024 13:19
Nov 19 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER ANNOUNCES UPDATE ON FDA NEW DRUG APPLICATION
FOR
KETAMINE
* PHARMATHER HOLDINGS LTD - FDA SCHEDULES POST-COMPLETE
LETTER
CLARIFICATION MEETING FOR DECEMBER 2, 2024
* PHARMATHER HOLDINGS LTD - INITIATES ACTIVITIES TO ADDRESS
CRL
DEFICIENCIES
* PHARMATHER HOLDINGS LTD - FDA REQUESTS NEW AND UPDATED
INFORMATION ON DRUG SUBSTANCE AND MANUFACTURING
* PHARMATHER HOLDINGS LTD - FDA HAS NO CONCERN ABOUT
STABILITY OF
KETAMINE SUBMISSION BATCHES
Source text: ID:nGNX2dxh3F
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application